Abstract: Compounds of the following backbone structure: which are useful as Tumor necrosis factor (TNF) inhibitors in treating disease related to elevated TNF.

Abstract: The instant invention relates to a new method for the synthesis of monomers and their use inter alia in the manufacture of semiconductive polymers. Monomers, in particular, asymmetric monomers, such as asymmetric fluorene compounds, are valuable material in the manufacture of semiconductive polymers. The know methods for producing asymmetric monomers, such as asymmetric fluorene compounds, are expensive due to the formation of by-products. The method according to the present invention avoids the formation of such by-products and is described in more detail in claims 1 to 14.

Abstract: A process for preparing a conjugated polymer, which comprises polymerizing in a reaction mixture (a) an aromatic monomer having at least two boron derivative functional groups selected from the group consisting of boronic acid groups, boronic ester groups, and borane groups, and an aromatic monomer having at least two reactive halide functional groups, or (b) an aromatic monomer having one reactive halide functional group and one boron derivative functional group selected from the group consisting of boronic acid groups, boronic ester groups, and borane groups, an amount of a catalyst suitable for catalyzing the polymerization of the aromatic monomers, and a base in an amount sufficient to convert the boron derivative functional groups into boron anionic groups, characterized in that the reaction mixture further comprises a first solvent and a second solvent with which said first solvent is substantially immiscible and an emulsifier in an amount sufficient to form an emulsion of the reaction mixture.

Abstract: A process for preparing high molecular weight polymers or copolymers by Suzuki coupling. The catalyst used in the process comprises a source of palladium and a source of a phosphine characterized in that at least one substituent on the phosphine is an ortho substituted aryl group. The process is suitable for the preparation of polymers for use in electronic and optoelectronic applications.

Abstract: Compounds of formula (I) are described in which R1 is optionally substituted heteroaryl; R2 is optionally substituted aryl or optionally substituted heteroaryl; R3 is a group -L1-R7 or -L2-R8 [where L1 is an optionally substituted alkylene linkage; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, —S(O)nR9, —NHSO2R9, —C(=Z)OR10, —C(=Z)R10, —OR10, —N(R11)—C(=Z)R9, —NY1Y2, —SO2—NY1Y2, —C(=Z)-NY1Y2, —N(R11)—C(=Z)-NY1Y2, —N(OR10)—C(=Z)-NY1Y2, —N(OR10)—C(=Z)R10, —C(=NOR10)R10, —C(=Z)NR10OR12, —N(R11)—C(═NR13)—NY1Y2 or —N(R11)—C(=Z)OR11; L2 is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; and R8 is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or heterocycloalk

Abstract: Compounds of formula (I) are described in which R1 is optionally substituted heteroaryl; R2 is optionally substituted aryl or optionally substituted heteroaryl; R3 is a group —L1—R7 or —L2—R8 [where L1 is an optionally substituted alkylene linkage; R7 is hydrogen, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, nitro, —S(O)nR9, —NHSO2R9, —C(═Z)OR10, —C(═Z)R10, —OR10, —N(R11)—C(═Z)R9, —NY1Y2, —SO2NY1Y2, —C(═Z)—NY1Y2, —N(R11)—C(═Z)—NY1Y2, —N(OR10)—C(═Z)—NY1Y2, —N(OR10)—C(═Z)R10, —C(═NOR10)R10, —C(═Z)NR10OR12, —N(R11)—C(═NR13)—NY1Y2 or —N(R11)—C(═Z)OR11; L2 is a direct bond or a straight- or branched-carbon chain comprising from 2 to about 6 carbon atoms and contains a double or triple carbon-carbon bond; and R8 is hydrogen, aryl, cycloalkenyl, cycloalkyl, heteroaryl or

Abstract: A system for adding multiple sets of numbers via a fixed-width adder includes an adder for receiving each of the sets of binary numbers at corresponding sets of adder inputs, and for generating a sum of each set of binary numbers. Each set of numbers defines a distinct data path through the adder. For each set of numbers, the system further includes a logic gate for inhibiting a carry path, from each portion of the adder corresponding to each carry path, to a next adjacent carry path. The system isolates two or more contiguous data paths through the fixed-width adder corresponding to each of the two or more sets of two binary numbers. The invention prevents unwanted signals from crossing summing lane boundaries in different processing modes. The same adder logic can thus be used for each processing mode by varying the combination of mode select control signals.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumours. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

Abstract: A device and method for utilizing a single clock signal to generate a digital data stream signal for transmission in a compressed domain transmission system. The device includes a plurality of packetized elementary stream encoders electronically coupled to a transport stream encoder electronically coupled to an output interface adapted to generate the digital data stream signal.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed on all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumor cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.

Abstract: In a compressed domain digital communications system, a method for reducing a variable latency associated with a buffer and at least partially resulting from at least one splice between a FROM bitstream and a TO bitstream each including data corresponding to a plurality of frames, the method including: selectively deleting data corresponding to a select at least one of the frames from the buffer based upon the variable latency so as to reduce the variable latency when an amount of data corresponding to a number of frames present in the buffer is greater than a given number of frames; and, regulating a flow of data in the system to prevent an underflow condition in the system by effecting a repeat last frame command and prevent an overflow condition in the system by slowing a rate of transmission for the data associated with at least one of the frames in the TO bitstream.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

Abstract: A method and apparatus for preserving audio and video presentation synchronization during the splicing operation by selectively deleting, if necessary, an audio/video access unit to avoid overlapping of audio/video frames in the spliced output stream.

Abstract: A method and apparatus for splicing a first compressed digital information stream into a second compressed digital information stream. The first information stream includes at least one entrance indicium identifying an appropriate stream entrance point, the second information stream includes at least one exit indicium identifying an appropriate stream exit point. A controller monitors the two streams until the appropriate points are found and, in response to a control signal, splices the first stream into the second stream.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen LK26, which is recognized by the murine antibody LK26. This antigen is expressed in all choriocarcinoma, teratocarcinoma and renal cancer cell lines whereas it is not expressed on cell lines of leukaemias, lymphomas, neuroectodermally-derived and epithelial tumour cell lines (excepting a small subset of epithelial cell lines). Furthermore, whereas renal cancer cell lines express the LK26 antigen, normal renal epithelial cells do not. Similarly, with the exception of the trophoblast, all normal adult and fetal tissues tested are negative for the LK26 phenotype. The invention also provides for numerous polynucleotide encoding humanized LK26 specific antibodies, expression vectors for producing humanized LK26 specific antibodies, and host cells for the recombinant production of the humanized antibodies.

Abstract: An apparatus and method for receiving an information stream comprising a plurality of timing portions and associated payload portions, decoding each timing portion, determining a duration parameter of a payload portion associated with the decoded timing portion, and recoding the timing portion using the duration parameter and a local reference time parameter.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

Abstract: A transmitted high definition television signal is represented by a packetized datastream configured as a sequence of data fields (FIG. 1) with a non-uniform data rate due to unequal inter-data overhead information intervals. Each data field is prefaced by a Field Sync overhead segment followed by 312 packetized data segments each with associated overhead information (FEC). At a transmitter (FIG. 33), a transport processor (14) forms data packets with associated headers and exhibits uninterrupted operation at a constant uniform data rate, while supplying a packetized datastream to a network (17) which constructs sequential data fields by inserting the non-data overhead information into the datastream. The transport processor is advantageously operated at a constant uniform data rate without having to modify the original data field structure to accommodate the needs of the data field construction network.